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ABSTRACT
In this study, we adapted the well known uracil DNA
glycosylase (UNG) carry-over prevention system for
PCR, and applied it to the analysis of DNA methy-
lation based on sodium bisulfite conversion. As
sodium bisulfite treatment converts unmethylated
cytosine bases into uracil residues, bisulfite treated
DNA is sensitive to UNG treatment. Therefore, UNG
cannot be used for carry-over prevention of PCR
using bisulfite treated template DNA, as not only
contaminating products of previous PCR, but also
the actual template will be degraded. We modified
the bisulfite treatment procedure and generated
DNA containing sulfonated uracil residues. Surpri-
singly, and in contrast to uracil, 6-sulfonyl uracil
containing DNA (SafeBis DNA) is resistant to UNG.
We showed that the new procedure removes up to
10 000 copies of contaminating PCR product in a
closed PCR vessel without significant loss of analy-
tical or clinical sensitivity of the DNA methylation
analysis.
INTRODUCTION
DNA methylation is the most well characterized epigenetic
DNA modiﬁcation. DNA methylation is known to play a
role in the regulation of gene expression during cell and can-
cer development. CpG island hypermethylation is one mecha-
nism repressing tumour suppressor genes in many cancers
(1–3). As genomic methylation patterns in somatic cells are
generally stable, a change in these patterns, such as aberrant
methylation of CpG island promoter regions, is a target for
cancer diagnosis and treatment (1,2). Recent results of early
cancer detection by identifying free-ﬂoating methylated can-
cer DNA in body ﬂuids, such as blood and urine demonstrate
the power of DNA methylation analysis (4–15).
Several PCR based assay formats have been developed to
identify differentially methylated tumour DNA (5,16,17). The
detection of a few methylated copies of a gene within a large
excess of unmethylated copies requires optimized assays with
the highest analytical sensitivity. The power of these PCR
assays is due to the bisulﬁte conversion of the DNA prior
to the analysis. As 5-methylcytosine and unmethylated cyto-
sine show the same base pairing properties, bisulﬁte treatment
of DNA is essential to transform epigenetic information
into nucleic acid sequence alterations. The treatment converts
unmethylated cytosines into uracil residues, but leaves
5-methylcytosines unconverted. It is thereby possible to anal-
yse the methylation information trough PCR based assays
(18,19). Although methylation sensitive restriction enzymes
combined with PCR have successfully been used for the iden-
tiﬁcation of methylated DNA without bisulﬁte conversion of
DNA, the clinical sensitivity and speciﬁcity of this approach
depends on the complete hydrolysis of unmethylated DNA,
generally being below 99%, and is limited to the single
CpG comprised by the restriction site (20,21).
Every PCR based system is susceptible to false positive
results caused by contamination with products from previous
reactions, and this is a major obstacle when used in diagnostic
laboratories for sensitive tests (22). Several approaches have
been reported to eliminate contamination by amplicons from
previous reactions in the PCR mix of a subsequent ampliﬁ-
cation (23–28). In the widely used uracil DNA glycosylase
(UNG) method, all PCRs in a laboratory are performed
with dUTP instead of dTTP. In contrast to the genomic tem-
plate DNA containing no uracil residues, PCR products can
be selectively destroyed by the enzyme UNG in the closed
vessel prior to PCR (29–32). However, this method is not
applicable if bisulﬁte converted DNA, which contains uracil
bases, is used as the template in PCR assays.
We have developed a modiﬁed bisulﬁte treatment method
to enable the utilization of the UNG carry-over prevention
method in methylation analysis. In this new procedure,
the DNA is not desulfonated after bisulﬁte treatment. The
bisulﬁte treatment itself generates sulfonated template DNA
(SafeBis DNA), which is resistant to UNG cleavage. After
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out with an elongated initial denaturation step. During this
step, the bisulﬁte DNA is desulfonated, the hot start Taq
DNA polymerase is activated, and the UNG is inactivated.
In this paper, we present the application of this novel proce-
dure to the sensitive detection of methylated DNA, in which
we applied the dUTP/UNG carry-over prevention method
to bisulﬁte treated template DNA, which was subsequently
analysed using the HeavyMethyl real-time PCR method.
MATERIAL AND METHODS
DNA preparation
The genomic DNA of 12 colon tumor (stage TN1-TN4)
samples and normal adjacent tissues (BioCat, Heidelberg,
Germany) was extracted using the QIAamp DNA mini kit
protocol (Qiagen, Hilden, Germany). The tumor samples
were obtained from ﬁve male and seven female patients.
Universal methylated human DNA (Chemicon International,
Inc., Temecula, CA) was used as reference DNA for quanti-
tative real-time PCR.
Preparation of Bisulfite DNA
For standard bisulﬁte treatment (Bisulﬁte DNA), 0.5 mg DNA
diluted in water was mixed with 354 ml of sodium bisulﬁte
solution (5.89 mol/l) and 146 ml of dioxane containing a
radical scavenger (6-hydroxy-2,5,7,8-tetramethylchromane-
2-carboxylic acid, 40 g/l). The reaction mixture was incu-
bated using the following conditions: 99 C for 3 min, 50 C
for 30 min, 99 C for 3 min, 50 C for 1.5 h, 99 C for 3 min
and ﬁnally 50 C for 3 h. The DNA was subsequently puriﬁed
by ultraﬁltration using Millipore Microcon columns YM30
(Millipore Corporation, Bedford, MA). The puriﬁcation was
conducted essentially according to the manufacturer’s
instructions. For this purpose, the reaction mixture was
mixed with 200 ml of water, loaded onto the ultraﬁltration
membrane, centrifuged for 15 min at 14 000 g, and subse-
quently washed with water. For desulfonation 100 mlo fa
0.2 mol/l NaOH solution was added and incubated for
10 min. A centrifugation for 10 min at 14 000 g was followed
by a ﬁnal washing step with water. The DNA was eluted from
the membrane with 75 ml of prewarmed TE buffer (50 C,
pH 8.5). Then the column was turned over and centrifuged
according to the manufacturer’s instructions to retrieve the
DNA from the membrane.
Preparation of SafeBis DNA
The preparation of SafeBis DNA was performed as described
above with the following exceptions: The incubation with
NaOH was omitted and replaced by a washing step with
100 ml water and the DNA was ﬁnally eluted from the
membrane with 75 ml prewarmed water (50 C).
Quantification of Bisulfite and SafeBis DNA by a
reference PCR
The total amount of bisulﬁte DNA was quantiﬁed using a
real-time reference PCR amplifying a 130 bp fragment within
the GSTP1 gene (GenBank accession no. X08058; nucleotide
2273–2402). The DNA amount was calculated against an
external standard curve prepared with known concentrations
of bisulﬁte converted universal methylated DNA. The
concentration of the standard DNA was determined by UV
at 260 nm after the bisulﬁte reaction. The PCR was per-
formed on a LightCycler instrument 2.0 in a total volume
of 20 ml containing 2 ml template DNA, 2 ml FastStart Light-
Cycler Mix for hybridization probes (Roche Diagnostics,
Mannheim, Germany), 3.5 mM MgCl2, 0.60 mM forward
primer: GGAGTGGAGGAAATTGAGAT, 0.60 mM reverse
primer: CCACACAACAAATACTCAAAAC and 0.2 mM
Taqman probe: FAM-TGGGTGTTTGTAATTTTTGTTTTG-
TGTTAGGTT-BHQ1 (where FAM ¼ carboxyﬂuorescein
and BHQ1 ¼ black whole quencher 1). The cycling condi-
tions of the reference PCR were as follows: 95 C for
10 min, followed by 50 cycles at 95 C for 10 s, 56 C for
30 s and 72 C for 10 s. The detection was carried out during
the annealing step at 56 C in channel F1 at 530 nm. For the
quantiﬁcation of SafeBis DNA, the cycling conditions were
changed as follows: 37 C for 10 min, 95 C for 30 min, fol-
lowed by 50 cycles at 95 C for 10 s, 56 C for 30 s and
72 C for 10 s.
Methylation specific real-time PCR
The TMEFF2-HeavyMethyl (HM) PCR selectively ampliﬁes
a 113 bp fragment of methylated bisulﬁte converted DNA in
the promoter region of TMEFF2 (GenBank accession no.
AF242221, nucleotide 1102–1214). The PCR was performed
on the LightCycler device using FastStart LightCycler Mix
for hybridization probes (Roche Diagnostics, Mannheim),
using 3.5 mM MgCl2, 0.30 mM forward primer:
AAAAAAAAAAAACTCCTCTACATAC, 0.30 mM reverse
primer: GGTTATTGTTTGGGTTAATAAATG, 4.0 mM
blocker: ACATACACCACAAATAAATTACCAAAAACA-
TCAACCAA-PH (where PH ¼ 30-phosphate modiﬁcation),
0.15 mM hybridization probe: TTTTTTTTTTCGGACGTCG-
TT-FL (where FL ¼ ﬂuorescein), and 0.15 mM hybridization
probe: red640-TCGGTCGATGTTTTCGGTAA-PH (where
red640 ¼ LightCycler ﬂuorescence label for channel
640 nm). The GSTP1-HM PCR (GenBank accession no.
X08058, nucleotide 1183–1304) was performed with
0.30 mM forward primer: GGGATTATTTTTATAAGGTT,
0.30 mM reverse primer: TACTAAAAACTCTAAACCCCA-
TC, 4.0 mM blocker: CCCATCCCCAAAAACACAAACCA-
CACAT-PH, 0.15 mM hybridization probe: TTCGTCGTCG-
TAGTTTTCGTT-FL, 0.15 mM hybridization probe: red640-
TAGTGAGTACGCGCGGTT-PH amplifying a 123 bp
fragment. The cycling conditions were as follows: 95 C for
10 min, then 50 cycles at 95 C for 10 s, 56 C for 30 s and
72 C for 10 s. The detection was carried out during the
annealing step monitoring the ratio of ﬂuorescence at 640
and 530 nm. The cycle thresholds (Cts) were calculated
according to the second derivative maximum method of the
LightCycler software.
For the carry-over prevention procedure, the real-time
PCRs were performed with the SafeBis DNA. In addition,
the PCR contained 0.2 U UNG (Roche Diagnostics,
Mannheim, Germany). The PCR cycling program was
changed to: 37 C for 10 min, 95 C for 30 min, followed
by 50 cycles at 95 C for 10 s, 56 C for 30 s and 72 C
for 10 s.
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Bisulfite and SafeBis template DNA
The positives signals of the GSTP1-HM, TMEEF2-HM and
reference PCR of 16 replicates were determined. In the
PCRs 0, 6, 12, 25 and 50 pg methylated Bisulﬁte or SafeBis
template DNA were used. Probit regression analysis of
percent positives versus log10 of pg template DNA/PCR
was performed with SPSS for Windows (version 13.0) soft-
ware. In addition, the 95% conﬁdence intervals (CI) were
determined at which 95% of the results were expected to be
positive. The amount of template DNA, which was detected
with a probability of 90% (LOD90), was deﬁned as detection
limit of the real time PCR. As the 95% CI becomes narrow at
the detection probability of 50%, the 95% CI of the LOD50
values were determined. PCRs, showing no overlap of the
95% CI of LOD50, have statistically signiﬁcant different
LOD50 values.
Calculation of the methylation rate
The relative level of gene methylation of the promoter of
TMEFF2 was calculated according to the PMR value method
(33), wherein the methylation level equals the percentage of
methylated copies measured in a sample by the TMEFF2-HM
assay in relation to the total DNA measured in the same sam-
ple by the reference PCR.
Generation of PCR contaminants
PCR ampliﬁcate was generated on methylated bisulﬁte
converted DNA as described above. Subsequently, the PCR
products were puriﬁed using the QIAquick PCR Puriﬁcation
Kit (Qiagen, Hilden, Germany) according to the manufac-
turers’ recommendation. Finally, the concentration of the
ampliﬁcate was determined by real-time PCR using bisulﬁte
converted universal methylated DNA as the quantiﬁcation
standard. For calculation, 33 ng standard bisulﬁte converted
DNA was assumed to represent 10 000 copies of gene product.
RESULTS
SafeBis DNA preparation and UNG carry-over
prevention
In order to use UNG for PCR product carry-over prevention
in PCR based methylation analysis using bisulﬁte converted
DNA, we developed the procedure shown in Figure 1. The
new method, generating SafeBis DNA, comprises thermal
denaturation of the DNA and subsequent sulfonation with
sodium bisulﬁte. In contrast to published procedures (18),
the sulfonated DNA was puriﬁed with a ﬁlter device using
water without desulfonation. The SafeBis DNA was stored
in water at  20 C until use. The desulfonation of the SafeBis
DNA was performed in the PCR vessel. For quantitative
desulfonation of the SafeBis DNA, the initial step activating
the polymerase at 95 C was prolonged from 10 to 30 min.
For carry-over prevention, the PCR contained 0.2 U UNG
and was incubated for 10 min at 37 C prior to the heat
activation step.
Standard bisulﬁte DNA (Bisulﬁte DNA), as prepared
according to published procedures, is a single stranded uracil
containing nucleic acid. As expected, 1 ng Bisulﬁte DNA
was not ampliﬁable after UNG treatment (Figure 2B), whereas
a Ct of 29.5 was determined for TMEFF2-HM PCR without
prior UNG treatment (Figure 2A). Under the described condi-
tions the SafeBis DNA was resistant to UNG (Figure 2B). The
UNG activity was tested with a dilution series of products of
the TMEFF2-HM PCR. Using up to 50 PCR cycles, 10 000
copies of the TMEFF2 PCR product contaminants were repro-
ducibly not ampliﬁed, if the PCR was incubated with UNG
prior to ampliﬁcation (Supplementary Figure 1).
The conditions for the desulfonation step in the PCR were
evaluated. The Ct differences of the GSTP1-HM PCR using
1 ng SafeBis and 1 ng Bisulﬁte DNA were measured for
different times of initial incubation at 95 C. If SafeBis
DNA was desulfonated for only 10 min at 95 C, the ampli-
ﬁcation of 1 ng SafeBis-DNA was delayed for 2.7 cycles
compared to 1 ng Bisulﬁte DNA. However, there was only
Figure 1. Carry-over prevention procedure for PCR using bisulfite treated
template DNA. Sulfonated uracils are a stable intermediate product of the
bisulfite treatment process. The SafeBis DNA is purified and used as a
template DNA for the PCR. For carry-over prevention the reaction is
incubated with UNG in closed reaction tubes prior to PCR. The SafeBis DNA
is not a substrate for UNG, but PCR amplificates containing uracil are
destroyed by UNG. As SafeBis DNA is not amplifiable by the Taq
polymerase, it needs to be desulfonated within the initial denaturation step of
the PCR. The UNG is inactivated in the same step.
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25 or 30 min. When TMEFF2-HM PCR was applied, the
ampliﬁcation of 1 ng SafeBis DNA was delayed for 0.5 Ct
using the described conditions (Table 1). In addition, differ-
ent PCR buffers were tested for their desulfonation ability.
Using the reference PCR, the FastStart reaction buffer
(Roche Diagnostics, Mannheim Germany) and the Quanti-
Tect Probe reaction buffer (Qiagen, Hilden Germany) showed
similar performance indicated by a 0.4 Ct delay of the
ampliﬁcation of 1 ng SafeBis DNA compared to standard
bisulﬁte treated DNA. In contrast, the ampliﬁcation of 1 ng
SafeBis DNA was delayed for 5.2 Ct, when qPCR Core Kit
(Eurogentec, Seraing, Belgium) was applied (Table 1 and
Supplementary Figure 2A–F).
Performance of the methylation specific real-time PCR
applying the carry over prevention work flow
In order to evaluate, if the sensitivity of detection is limited
by the application of the carry over prevention workﬂow,
the performances of different real-time PCRs were compa-
ratively analysed. The 50% limit of detection (LOD50) of
3 real-time PCR on SafeBis and Bisulﬁte DNA were
determined. As these values showed overlapping conﬁdence
intervals for the individual PCRs, there was no statistically
signiﬁcant difference in the sensitivity of the assays, when
using either SafeBis or Bisulﬁte DNA as template (Table
2). The 90% detection limits (LOD90) determined for the
TMEFF2-HM, GSTP1-HM and the reference PCR on
SafeBis DNA were 16.1, 16.1 and 16.3 pg, respectively.
Supplementary Figure 3 shows the detailed results of the
LOD determination.
Also, the PCR efﬁciency of real-time PCRs was not signiﬁ-
cantly changed using SafeBis DNA as compared to Bisulﬁte
DNA. Using dilution series of 20, 5, 2, 0.8 and 0.2 ng methy-
lated SafeBis DNA, the TMEFF2-HM assay showed an efﬁ-
cency of 1.85 compared to an efﬁciency of 1.82 on Bisulﬁte
DNA. The efﬁcencies of the reference PCR were determined
with 1.99 (SafeBis DNA) and 1.98 (Bisulﬁte DNA), respec-
tively. The data points showed a good alignment with R
2 >
0.99, when the log10 DNA amount was plotted as a function
of Ct (Supplementary Figure 2A, B, C and D). These data
indicate that SafeBis DNA (i) is not a substrate for UNG,
and (ii) is sufﬁciently desulfonated by the PCR during the ini-
tial incubation at 95 C for 30 min.
Stability of SafeBis DNA under different storage
conditions
Due to the low stability of the sulfonyl group at the
C6-position of the uracil at elevated pH values, the storage
conditions of SafeBis DNA at pH 7, pH 8 and pH 9 were
investigated with the GSTP1-HM PCR. SafeBis DNA was
stable for 144 h when stored at 4–8 C and pH 7 (Table 3).
Figure 2. Susceptibility of Bisulfite DNA and SafeBis DNA to UNG
treatment. Detection of methylated DNA with the TMEFF2-HM real-time
PCR using 1 ng Bisulfite DNA (open squares), SafeBis DNA (black squares)
and 10 000 copies of TMEFF2 PCR product (black triangles). Broken lines
indicate no template controls. The PCR products were previously generated
with dUTP. Whereas all three different template DNAs are amplified without
prior UNG treatment (A), only the SafeBis DNA shows amplification after
UNG treatment (B). The treatment was performed with 0.2 U UNG in closed
PCR vessels for 10 min at 37 C.











GSTp1-HM 10 2.7 Nd Nd
15 1.9 Nd Nd
20 0.6 Nd Nd
25 0.2 Nd Nd
30 0.2 Nd Nd
TMEFF2-HM 30 0.5 Nd Nd
Reference-PCR 30 0.4 0.4 5.2
adetermined as (Ct of 1 ng SafeBis DNA)—(Ct of 1 ng Bisulfite DNA).
Table 2. Determination of the detection limits of three real-time PCRs on
SafeBis and Bisulfite template DNA
PCR SafeBis DNA Bisulfite DNA
LOD50 (pg)
a 95% CI (pg)
b LOD50 (pg)
a 95% CI (pg)
b
GSTP1-HM 4.9 2.3–6.9 4.8 0.5–8.1
TMEFF2-HM 7.0 3.7–9.3 4.1 0.0–6.8
Reference-PCR 5.7 1.3–8.3 6.9 2.7–9.9
a50% detection limits were calculated by a Probit regression analysis based on
the results using 50, 25, 12, 6 and 0 pg methylated DNA analysed in 16 repli-
cates each.
b95% confidence interval of LOD50 value.
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3000 copies of GSTP1 PCR product, 10, 1 and 0.1 ng SafeBis
template DNA stored at 4–8 C and pH 7 for up to 144 h
showed comparable performance to the standard bisulﬁte
DNA without UNG treatment. The cycle thresholds were
increased by a maximum of 0.3 Ct when compared to the
same amount of standard bisulﬁte converted DNA. Storage
at 40 C, particularly at pH 9, caused signiﬁcant desulfonation
of the SafeBis template DNA. No ampliﬁcation was detected
on 0.1 ng SafeBis DNA stored under these conditions. Using
1 and 10 ng SafeBis DNA, the Cts were increased by 6.4 and
4.9, respectively. At  20 C and pH 7 no signiﬁcant desul-
fonation of SafeBis DNA was detected up to a storage time
of 2 weeks (data not shown).
Methylation analysis of clinical samples using
SafeBis DNA
The new procedure was investigated on a subset of 12
matched sample pairs of normal and colon cancer tissue.
After DNA extraction 500 ng of tissue DNA was bisulﬁte
treated with the two procedures described in this study. The
TMEFF2-HM PCR was performed on bisulﬁte DNA, SafeBis
DNA and SafeBis DNA spiked with 10000 copies of
TMEFF2 ampliﬁcate generated on bisulﬁte converted univer-
sally methylated DNA. The total amounts of bisulﬁte DNA
and SafeBis DNA were determined by the reference assay
without prior UNG treatment. Subsequently, the PMR value
of the TMEFF2 promoter fragment was determined. The
PMR values of TMEFF2, determined on SafeBis and SafeBis
DNA spiked with 10 000 copies of TMEFF2 ampliﬁcates,
were highly correlated with R
2 ¼ 0.982 (Figure 3A). The
methylation signal was not inﬂuenced by the addition of up
to 10 000 copies of PCR contaminants. This indicates that
the re-ampliﬁcation of contaminants was efﬁciently pre-
vented by the presented technology. Furthermore, a high cor-
relation (R
2 ¼ 0.958) between the PMR values of TMEFF2
determined on standard bisulﬁte DNA and SafeBis DNA
spiked with 10 000 copies of TMEFF2 was observed
(Figure 3B). These results demonstrate that TMEFF2-HM
PCR showed the same analytical results using either SafeBis
DNA or standard bisulﬁte DNA as template DNA.
DISCUSSION
Cross-contamination by previously generated PCR products
is a serious problem for PCR based assays in clinical
Table 3. Stability of SafeBis DNA under different storage conditions
Ct of GSTP1 HM real-time PCR assay
a


































b   ++ +   ++ +   ++ +   ++ +
10 ng template 26.8      27.2 27.4 27.3 28.5 27.0 27.9 27.3 30.4 27.0 28.1 28.2 33.2
1 ng template 30.4      31.0 31.3 31.6 32.1 31.6 31.4 31.3 34.0 31.7 31.9 31.8 35.3
0.1 ng template 34.6      34.9 34.7 35.2 36.3 36.2 35.9 36.1   35.5 36.2 35.4  
aThe mean of triplicate experiments is shown;   indicates no amplification curve.
b+: 0.2 U UNG were added and the reaction incubated for 10 min 37 C prior to PCR.
Figure 3. Methylation analysis of the promoter region of TMEFF2. 12 colon
cancer (black) and 12 healthy adjacenttissues (white) were processed with and
without carry-over prevention procedure. The PMR values were calculated
from the ratio of DNA values obtained by TMEFF2-HM and a reference real-
timePCR.(A)ResultsfromtwomeasurementsofSafeBisDNAusingUNGfor
carry-over prevention are plotted. The values on the y-axis were obtained from
samplesspikedwith10000copiesofuracilcontainingTMEFF2PCRproducts,
representing a carry-over contamination. On the x-axis, the PMR values from
the sameSafeBisDNA samples,withoutspikedamplificates,wereplotted.(B)
A correlation plot of the results from the standard method without carry-over
prevention (x-axis) and the results obtained from SafeBis DNA spiked with 10
000 copies contaminating PCR products and prior UNG treatment (y-axis).
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DNA based on its epigenetic properties. Although alternative
methods that allow for the enzymatic sterilization of single
closed PCR vessels have been developed (25,34), the
dUTP/UNG method exhibits some major advantages. The
dUTP/UNG method destroys double stranded and single
stranded uracil containing DNA fragments, a single abasic
site generated by UNG inactivates the contaminating PCR
product as a template for the next PCR. Therefore, the
dUTP/UNG is a highly effective carry-over prevention tech-
nique (31). Another method using type IIS restriction
enzymes requires 50-modiﬁed primers and is not applicable
with established PCR assays (34). In addition, single stranded
PCR ampliﬁcates might be either not, or only incompletely
destroyed. The UNG technology is, to our knowledge, the
only ‘closed vessel’ carry-over prevention method for PCR
based diagnostic screening assays.
In this paper we present, a new procedure that enables the
use of the dUTP/UNG system as a carry-over prevention sys-
tem for DNA methylation detection with PCR using bisulﬁte
converted DNA as the template. The workﬂow combines a
modiﬁed bisulﬁte treatment procedure that generates 6-
sulfonyl uracil containing DNA with an elongated initial
activation step of hot start Taq polymerase in order to obtain
also a complete desulfonation of the template DNA in the
PCR. In contrast to uracil containing DNA molecules, such
as standard bisulﬁte converted DNA, the sulfonated DNA
is not a substrate for the UNG. Under the conditions used,
no signiﬁcant loss of HM real-time PCR performance was
detected using SafeBis DNA in comparison to bisulﬁte
treated DNA prepared with standard procedures.
As only SafeBis DNA is resistant to UNG, the storage
conditions of SafeBis DNA are very important for avoiding
inadvertent desulfonation. The sulfonyl residue of the uracil
is easily hydrolyzed at alkaline pH and elevated temperatures.
Accordingly, SafeBis becomes sensitive to UNG if stored at
pH 8–9 and higher temperatures. However, SafeBis DNA
stored at pH 7 is stable for several days at 4–8 Co ru pt o
2 weeks at  20 C. However, a complete desulfonation of
uracil is necessary for effective ampliﬁcation of the SafeBis
DNA. DNA containing 6-sulfonyl uracil is not a template
for Taq polymerases. The desulfonation happens during the
initial heat denaturation step of the PCR at 95 C, at the
same time inactivation of the UNG occurs. An initial PCR
activation of 25 or 30 min showed the best results; a shorter
initial activation step reduced the PCR efﬁciency by incom-
plete desulfonation of the SafeBis DNA. A longer activation
step is not recommended, because of partial deactivation of
the Taq polymerase. Furthermore, we tested the SafeBis
DNA desulfonation capabilities of two additional PCR sys-
tems. The QuantiTect Kit (Qiagen, Hilden, Germany) showed
comparable results to the FastStart LightCycler Mix (Roche
Diagnostics, Mannheim, Germany). However, desulfonation
using the qPCR Core Kit (Eurogentec, Seraing) was less efﬁ-
cient compared to the other PCR buffers. As a higher desul-
fation efﬁciency is expected in a more alkaline solution, the
pH of the individual buffers, in combination with the reaction
time, is a critical parameter. Both, the FastStart LightCycler
Mix and the QuantiTect Kit have a pH 8.3–8.5, in contrast
to the qPCR Core Kit with pH 7.9. The results demonstrate
that quantitative desulfonation within the PCR initial
denaturation step is achievable, but might vary between
buffers, which therefore need to be tested previously.
The application of the carry-over prevention on clinical
samples was also successful. Using the new procedure, the
measured methylation values of colon samples in the pres-
ence of 10 000 copies of contaminating PCR product showed
high correlation with those determined with the standard
method lacking any contamination. The data also suggest,
that putative PCR artefacts due to incomplete desulfonation
did not interfere in a major way with the analysis. Up to
now, four different HM assays showing detection limits of
10–25 pg methylated DNA, were successfully tested with
the present carry-over prevention procedure. In this work,
up to 10 000 copies of TMEFF2-HM PCR products were
reproducibly neutralized by the work ﬂow presented. At
least 3000 copies of products of the GSTP1-HM and the
reference PCR were not ampliﬁed after UNG treatment
(data not shown). Based on the LODs of the individual
PCRs (LOD90 ¼ max. 16.3 pg;  5 copy equivalents), the
efﬁciency of degradation of PCR products was found to be
between 99.8 and 99.95%. The variability of sterilization
rates might be dependent on the fragment length and the
uracil content of the PCR product. Nevertheless, the deter-
mined degradation rates were in the range described for
other quantitative real-time PCRs (35). This paper describes,
for the ﬁrst time, a PCR carry-over prevention procedure
that can be used with bisulﬁte converted DNA—a prerequi-
site for high throughput epigenetic analysis in diagnostic
laboratories.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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